Novonesis
Novonesis (CPH: NSIS B) is a publicly traded Industrial Biomanufacturing company founded in 2024 and based in Bagsværd, Denmark.
Novonesis was founded in 2024 and is headquartered in Bagsværd, Denmark. The company builds industrial biosolutions, including enzymes and probiotic cultures. Its product line includes Stainzyme, an amylase used in laundry and dishwashing detergents to lift starch-based stains at low wash temperatures; Cellic CTec, a cellulase blend sold to bioethanol producers to convert agricultural residues into fermentable sugars; and the BB-12 and LGG probiotic strains supplied to dairy, infant formula, and supplement manufacturers as functional ingredients. Revenue is derived from selling these products to industrial customers. The company trades on Nasdaq Copenhagen under the ticker NSIS B, and it has no disclosed venture funding history. Its CEO is Ester Baiget.
Novonesis supplies enzymes and microbial ingredients across household care, biofuel, and food and health markets, placing it in the industrial biomanufacturing layer that other manufacturers buy from. Its Cellic CTec product targets second-generation ethanol production from non-food feedstocks such as corn stover and bagasse. Its probiotic strains, BB-12 and LGG, are supplied as validated ingredients to dairy, infant formula, and supplement makers. The company is listed on Nasdaq Copenhagen and reports a headcount range of 10,000 or more.
At a glance
Total raised
Undisclosed
Headcount
10k+
Headquarters
Bagsværd
DenmarkFounded
2024
Status
Public
Subsector
Funding history
Total raised
—
Rounds tracked
0
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Stock performance
In the news
Novonesis · last 30 days
No articles ingested yet for Novonesis. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Leadership
Ester Baiget
President & CEO